ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Approval of asciminib was first granted by the United States Food and Drug Administration (FDA) in 2021 for the treatment of adults with Philadelphia-positive CML in chronic phase (CP) previously treated with ≥2 TKIs and for those with the BCR::ABL1 T315I mutation [12].